STOCK TITAN
  1. Home
  2. Sec-filings
  3. SPRY
  4. [Form 4] ARS Pharmaceuticals, Inc. Insider Trading Activity

ARS Pharmaceuticals (SPRY) director Saqib Islam granted 30,000 stock options at $10.54

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

ARS Pharmaceuticals director Saqib Islam received a stock option grant covering 30,000 shares of Common Stock. The option has an exercise price of $10.54 per share and expires on June 23, 2036. These options vest in full on the earlier of June 24, 2027 or the company’s 2027 annual meeting of stockholders. Following this grant, Islam holds 30,000 stock options directly.

Positive

  • None.

Negative

  • None.
Insider Islam Saqib
Role null
Type Security Shares Price Value
Grant/Award Stock Option (right to buy) 30,000 $0.00 --
Holdings After Transaction: Stock Option (right to buy) — 30,000 shares (Direct, null)
Footnotes (1)
  1. [object Object]
Option grant size 30,000 options Stock Option (right to buy) covering Common Stock
Exercise price $10.54 per share Conversion or exercise price of stock option
Expiration date June 23, 2036 Option expiration date
Vesting trigger date June 24, 2027 Vests on earlier of this date or 2027 annual meeting
Post-grant option holdings 30,000 options Total derivative shares following transaction
Stock Option (right to buy) financial
"security_title: "Stock Option (right to buy)""
exercise price financial
"conversion_or_exercise_price: "10.5400""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vest in full financial
"The shares subject to the option will vest in full on the earlier of June 24, 2027"
annual meeting of stockholders financial
"or the date of the Issuer's 2027 annual meeting of stockholders"
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Islam Saqib
(Last)(First)(Middle)
C/O ARS PHARMACEUTICALS, INC.
11682 EL CAMINO REAL, SUITE 300
(Street)
SAN DIEGO CALIFORNIA 92130
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
ARS Pharmaceuticals, Inc. [ SPRY ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/24/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (right to buy)$10.5406/24/2026A30,000 (1)06/23/2036Common Stock30,000$030,000D
Explanation of Responses:
1. The shares subject to the option will vest in full on the earlier of June 24, 2027 or the date of the Issuer's 2027 annual meeting of stockholders, which date has not been set by the Issuer's Board of Directors.
/s/ Kathleen Scott, Attorney-in-Fact06/26/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did ARS Pharmaceuticals (SPRY) director Saqib Islam report in this Form 4?

Saqib Islam reported receiving a stock option grant for 30,000 shares of ARS Pharmaceuticals Common Stock. The options are a compensation-related award, not an open-market purchase or sale, and give him the right to buy shares at a fixed price in the future.

How many ARS Pharmaceuticals (SPRY) options did Saqib Islam receive and at what price?

He received 30,000 stock options, each with an exercise price of $10.54 per share. This means he can purchase up to 30,000 ARS Pharmaceuticals shares at $10.54, regardless of the market price, once the options are vested and exercisable.

When do Saqib Islam’s ARS Pharmaceuticals (SPRY) stock options vest?

The 30,000 stock options will vest in full on the earlier of June 24, 2027 or the date of ARS Pharmaceuticals’ 2027 annual meeting of stockholders. Vesting must occur before the options can be exercised to purchase Common Stock.

When do Saqib Islam’s ARS Pharmaceuticals (SPRY) stock options expire?

These stock options expire on June 23, 2036. After that expiration date, any unexercised options become worthless. Islam must both wait for vesting and exercise before expiration to acquire ARS Pharmaceuticals Common Stock under this grant.

Is this ARS Pharmaceuticals (SPRY) Form 4 a market trade or a compensation grant?

This Form 4 reports a grant or award acquisition of stock options, not a market trade. The company awarded 30,000 options as compensation, giving Saqib Islam a potential future right to buy shares at $10.54 instead of reporting an open-market buy or sell.

How many ARS Pharmaceuticals (SPRY) options does Saqib Islam hold after this transaction?

After this grant, Saqib Islam holds 30,000 stock options directly, as indicated by the total shares following the transaction. The filing does not list additional derivative positions in the derivative summary beyond this new award.